BioCentury
ARTICLE | Company News

Meiji licenses compounds to MediciNova, Cerexa

November 2, 2006 12:52 AM UTC

Meiji Seika Kaisha (Tokyo, Japan) was active on Wednesday, striking separate deals in which it granted MediciNova (Osaka:4875) and Cerexa (Alameda, Calif.) licenses for preclinical cardiovascular and infectious disease compounds, respectively. MediciNova received a worldwide license to develop and commercialize Meiji's MN-447 and MN-462 antithrombotic compounds for cardiovascular disease. The license excludes Japan and certain Asian countries. MN-447 is a cardioprotective, anti-platelet agent that acts as a dual antagonist of glycoprotein IIb/IIIa ( GPIIb/IIIa) and integrin alpha(5)beta(1) receptors. MN-462 is a selective inhibitor of plasma carboxypeptidase B, a key antifibrinolytic enzyme. ...